Endothelin: Key mediator of hypertension in preeclampsia

American Journal of Hypertension

Volumn 24, Issue 9, 2011, Pages 964-969

  George, Eric M ^a   Granger, Joey P ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

AT1 AA; blood pressure; endothelin 1; hypertension; preeclampsia; pregnancy induced hypertension; sFlt 1; VEGF

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; CYTOKINE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; GELATINASE A; HYPOXIA INDUCIBLE FACTOR; NITRIC OXIDE; PREPROENDOTHELIN; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; AUTOIMMUNITY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HYPERTENSION; HYPOXIA; ISCHEMIA; MATERNAL HYPERTENSION; MYOMETRIUM; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR BLOCKING; REPRODUCTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANIMALS; AUTOANTIBODIES; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 80052038097     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.99     Document Type: Article

References (67)

1. Roberts JM, Pearson GD, Cutler JA, Lindheimer MD; National Heart Lung and Blood Institute. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy 2003; 22:109-127.
2. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Bottoms SF, Das A, Roberts JM, McNellis D. The preterm prediction study: risk factors for indicated preterm births. Maternal- Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol 1998; 178:562-567. (Pubitemid 28207511)
3. Caritis S, Sibai B, Hauth J, Lindheimer M, VanDorsten P, Klebanoff M, Thom E, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G, Dombrowski M, McNellis D, Roberts J. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1998; 179:946-951. (Pubitemid 28489286)
4. Turner JA. Diagnosis and management of pre-eclampsia: an update. Int J Womens Health 2010; 2:327-337.
5. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115:365-375.
6. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2:543-549.
7. Khong Y, Brosens I. Defective deep placentation. Best Pract Res Clin Obstet Gynaecol 2011; 25:301-311.
8. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1:177-191.
9. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 1992; 80: 283-285.
10. Rajakumar A, Doty K, Daftary A, Harger G, Conrad KP. Impaired oxygendependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta 2003; 24:199-208. (Pubitemid 37184716)
11. Rajakumar A, Whitelock KA, Weissfeld LA, Daftary AR, Markovic N, Conrad KP. Selective overexpression of the hypoxia-inducible transcription factor, HIF- 2alpha, in placentas from women with preeclampsia. Biol Reprod 2001; 64: 499-506. (Pubitemid 32109738)
12. Sheppard BL, Bonnar J. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol 1981; 88:695-705. (Pubitemid 11052966)
13. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010; 14:528-552.
14. Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006; 108:338-344. (Pubitemid 44305675)
15. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658. (Pubitemid 36278583)
16. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95:884-891. (Pubitemid 39435003)
17. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145:4838-4845. (Pubitemid 39551100)
18. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1085-R1093. (Pubitemid 44498450)
19. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 2009; 22:564-568.
20. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55:394-398.
21. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50:686-692. (Pubitemid 47442732)
22. Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009; 54:1129-1135.
23. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, da Costa Gonzalves AC, Grone HJ, Ahmed A, Weich HA. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2009; 14:1857-1867.
24. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010; 55:380-385.
25. Sunderland N, Hennessy A, Makris A. Animal Models of Pre-eclampsia. Am J Reprod Immunol 2011; 65:533-541.
26. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415. (Pubitemid 18090241)
27. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1388-R1392.
28. Deng LY, Day R, Schiffrin EL. Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol 1996; 7:1158-1164. (Pubitemid 27468267)
29. Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl saltsensitive rats. Hypertension 1998; 31:397-402.
30. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25:1135-1143.
31. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29:2-26. (Pubitemid 27020792)
32. Michel H, Bäcker A, Meyer-Lehnert H, Migas I, Kramer HJ. Rat renal, aortic and pulmonary endothelin-I receptors: effects of changes in sodium and water intake. Clin Sci 1993; 85:593-597. (Pubitemid 23336545)
33. Migas I, Bäcker A, Meyer-Lehnert H, Michel H, Wulfhekel U, Kramer HJ. Characteristics of endothelin receptors and intracellular signalling in porcine inner medullary collecting duct cells. Am J Hypertens 1993; 6:611-618. (Pubitemid 23248828)
34. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41:851-876. (Pubitemid 32385909)
35. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007; 47:731-759.
36. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990; 71:1675-1677. (Pubitemid 120032795)
37. Baksu B, Davas I, Baksu A, Akyol A, Gulbaba G. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. Int J Gynaecol Obstet 2005; 90:112-117. (Pubitemid 40981947)
38. Nishikawa S, Miyamoto A, Yamamoto H, Ohshika H, Kudo R. The relationship between serum nitrate and endothelin-1 concentrations in preeclampsia. Life Sci 2000; 67:1447-1454. (Pubitemid 30658702)
39. Maltaris T, Scalera F, Schlembach D, Hoffmann I, Mueller A, Binder H, Goecke T, Hothorn T, Schild RL, Beckmann MW, Dittrich R. Increased uterine arterial pressure and contractility of perfused swine uterus after treatment with serum from preeclamptic women and endothelin-1. Clin Sci 2005; 109:209-215. (Pubitemid 41117305)
40. Ajne G, Wolff K, Fyhrquist F, Carlström K, Hemsén- Mörtberg A, Nisell H. Endothelin converting enzyme (ECE) activity in normal pregnancy and preeclampsia. Hypertens Pregnancy 2003; 22:215-224. (Pubitemid 37288685)
41. Ajne G, Ahlborg G, Wolff K, Nisell H. Contribution of endogenous endothelin-1 to basal vascular tone during normal pregnancy and preeclampsia. Am J Obstet Gynecol 2005; 193:234-240. (Pubitemid 40991851)
42. Lee KJ, Kim MK, Park YH, Seol HJ, Lim JE, Lee JN, Oh MJ. Vascular endothelial growth factor induces endothelin-1 production via matrix metalloproteinase-2 rather than endothelin-converting enzyme-1. Hypertens Pregnancy 2007; 26: 189-199. (Pubitemid 46676544)
43. Napolitano M, Miceli F, Calce A, Vacca A, Gulino A, Apa R, Lanzone A. Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas. J Clin Endocrinol Metab 2000; 85:2318-2323. (Pubitemid 32269262)
44. Faxén M, Nasiell J, Lunell NO, Blanck A. Differences in mRNA expression of endothelin-1, c-fos and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia and/or intrauterine growth retardation. Gynecol Obstet Invest 1997; 44:93-96. (Pubitemid 27387328)
45. Fiore G, Florio P, Micheli L, Nencini C, Rossi M, Cerretani D, Ambrosini G, Giorgi G, Petraglia F. Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia. J Clin Endocrinol Metab 2005; 90:4205-4210. (Pubitemid 41058198)
46. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, Bennett WA, Granger JP. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001; 37:1191-1195. (Pubitemid 32304024)
47. Abitbol MM, Ober MB, Gallo GR, Driscoll SG, Pirani CL. Experimental toxemia of pregnancy in the monkey, with a preliminary report on renin and aldosterone. Am J Pathol 1977; 86:573-590. (Pubitemid 8063539)
48. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71:977-984. (Pubitemid 46741987)
49. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP.Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001; 37:485-489. (Pubitemid 32199016)
50. Roberts L, LaMarca BB, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006; 47:615-618. (Pubitemid 43843885)
51. Nash P, Wentzel P, Lindeberg S, Naessén T, Jansson L, Olovsson M, Eriksson UJ. Placental dysfunction in Suramin-treated rats-a new model for pre-eclampsia. Placenta 2005; 26:410-418. (Pubitemid 40567919)
52. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54:652-658.
53. Xia Y, Kellems RE. Is preeclampsia an autoimmune disease? Clin Immunol 2009; 133:1-12.
54. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Mol Aspects Med 2007; 28:192-209. (Pubitemid 46843191)
55. Schiessl B. Inflammatory response in preeclampsia. Mol Aspects Med 2007; 28:210-219. (Pubitemid 46843193)
56. Kupferminc MJ, Peaceman AM, Wigton TR, Rehnberg KA, Socol ML. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994; 170:1752-1757; discussion 1757.
57. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995; 102:20-25.
58. LaMarca B, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, Granger JP. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension 2008; 52: 1161-1167.
59. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005; 46:82-86. (Pubitemid 40946495)
60. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 1992; 262:C854-C861.
61. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107:1632-1639. (Pubitemid 36401560)
62. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 2006; 91:2424-2427. (Pubitemid 43855036)
63. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension 2008; 52:1168-1172.
64. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr, Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009; 54:905-909.
65. Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, Kumada M, Hammer RE, Yanagisawa M. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998; 125:813-824. (Pubitemid 28142824)
66. Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2009; 10:1847-1858.
67. Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET(A) receptors. Life Sci 2003; 74:405-409.